Justin Sullivan/Getty Images News WhatsApp ( META ) will allow AI chatbots from rivals on its platform in Europe by charging them a fee, after the bloc's regulator found that the Meta-owned messaging app was taking advantage of its market position and restricting outside players. The EU's findings were part of a broader probe launched into Meta in December last year after the company introduced a ...
Justin Sullivan/Getty Images News WhatsApp ( META ) will allow AI chatbots from rivals on its platform in Europe by charging them a fee, after the bloc's regulator found that the Meta-owned messaging app was taking advantage of its market position and restricting outside players. The EU's findings were part of a broader probe launched into Meta in December last year after the company introduced a policy in October to not allow external AI chatbots for business communication on WhatsApp. "For the next 12 months, we'll support general purpose AI chatbots using the WhatsApp Business API in Europe in response to the European Commission's regulatory process," a spokesperson for WhatsApp said Thursday. "We believe that this removes the need for any immediate intervention as it gives the European Commission the time it needs to conclude its investigation," the spokesperson said. Meta said general AI chatbot providers will pay the company about €0.0490 to €0.1323 per non-template message, depending on the country. The final amount could be hefty for service providers if chatbot conversations become lengthy. " The Commission is assessing the impact of these changes on its investigation into temporary measures, as well as on the broader antitrust investigation on its merits," a spokesperson for the European Commission said. In January, Meta allowed AI chatbots in Italy after an order from the country's antitrust watchdog, which is separately investigating the company's AI policy. Meta said the changes will also apply in Brazil following a Wednesday court decision to reinstate an injunction on the company related to an investigation similar to the ones ongoing in the EU and Italy. More on Meta Meta: Time To Sit On The Fence (Downgrade) Meta Platforms, Inc. (META) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Meta Platforms: The Growth Machine That Keeps On Giving Tech sector volatility creates ‘interesting time to step in’ – Evercore’s Ma...
Justin Sullivan/Getty Images News WhatsApp ( META ) will allow AI chatbots from rivals on its platform in Europe by charging them a fee, after the bloc's regulator found that the Meta-owned messaging app was taking advantage of its market position and restricting outside players. The EU's findings were part of a broader probe launched into Meta in December last year after the company introduced a ...
Justin Sullivan/Getty Images News WhatsApp ( META ) will allow AI chatbots from rivals on its platform in Europe by charging them a fee, after the bloc's regulator found that the Meta-owned messaging app was taking advantage of its market position and restricting outside players. The EU's findings were part of a broader probe launched into Meta in December last year after the company introduced a policy in October to not allow external AI chatbots for business communication on WhatsApp. "For the next 12 months, we'll support general purpose AI chatbots using the WhatsApp Business API in Europe in response to the European Commission's regulatory process," a spokesperson for WhatsApp said Thursday. "We believe that this removes the need for any immediate intervention as it gives the European Commission the time it needs to conclude its investigation," the spokesperson said. Meta said general AI chatbot providers will pay the company about €0.0490 to €0.1323 per non-template message, depending on the country. The final amount could be hefty for service providers if chatbot conversations become lengthy. " The Commission is assessing the impact of these changes on its investigation into temporary measures, as well as on the broader antitrust investigation on its merits," a spokesperson for the European Commission said. In January, Meta allowed AI chatbots in Italy after an order from the country's antitrust watchdog, which is separately investigating the company's AI policy. Meta said the changes will also apply in Brazil following a Wednesday court decision to reinstate an injunction on the company related to an investigation similar to the ones ongoing in the EU and Italy. More on Meta Meta: Time To Sit On The Fence (Downgrade) Meta Platforms, Inc. (META) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Meta Platforms: The Growth Machine That Keeps On Giving Tech sector volatility creates ‘interesting time to step in’ – Evercore’s Ma...
The recent dip in On Holding (NYSE: ONON) shares following its 2026 guidance may be a great gift for long-term investors. Wall Street was disappointed in a conservative revenue outlook, but the underlying fundamentals tell a story of a premium brand in its prime. Revenue growth continues to compound at a 20%+ rate, margins are higher than expected, and the value looks too good to pass up. I dig in...
The recent dip in On Holding (NYSE: ONON) shares following its 2026 guidance may be a great gift for long-term investors. Wall Street was disappointed in a conservative revenue outlook, but the underlying fundamentals tell a story of a premium brand in its prime. Revenue growth continues to compound at a 20%+ rate, margins are higher than expected, and the value looks too good to pass up. I dig into everything you need to know, including how currencies complicate analyzing the business, in this video. *Stock prices used were end-of-day prices of March 4, 2026. The video was published on March 5, 2026. Continue reading
Earnings Call Insights: Invivyd (IVVD) Q4 2025 Management View Marc Elia, Chairman, introduced Dr. [indiscernible] as the new Chief Medical Officer, noting, "While Michael is unable to join our call this morning, I'm sure many of you will enjoy hearing from him going forward." Elia reported the Revolution clinical program is "well underway with the aim of providing Americans with an option for wha...
Earnings Call Insights: Invivyd (IVVD) Q4 2025 Management View Marc Elia, Chairman, introduced Dr. [indiscernible] as the new Chief Medical Officer, noting, "While Michael is unable to join our call this morning, I'm sure many of you will enjoy hearing from him going forward." Elia reported the Revolution clinical program is "well underway with the aim of providing Americans with an option for what we believe is needed protection from symptomatic COVID disease." He emphasized progress with PEMGARDA and pre-commercial preparations for VYD2311, stating, "Our commercial work with PEMGARDA continues, and we were pleased to demonstrate growth in the fourth quarter." Elia highlighted the expansion of Invivyd's monoclonal antibody pipeline, announcing, "We are excited to begin clinical exploration of our antibodies in long COVID and post-vaccination syndrome as disclosed earlier this quarter." He also referenced a new RSV antibody with "properties...highly competitive with standard of care." Elia addressed the DECLARATION study for VYD2311: "We were recently notified that the DECLARATION clinical trial has reached target enrollment...may modestly over enroll as sites are permission to complete any ongoing screening and enrollment before closing." On regulatory feedback, Elia shared, "Recently, the DECLARATION Independent Data Monitoring Committee...conducted a prespecified review...and we are pleased to relay their written communication...pregnant and breast-feeding women may now enroll in the study;...women of child-bearing age enrolled in the study are no longer required to use contraception; and...prespecified safety visits...are no longer required." Timothy Lee, Chief Commercial Officer, noted, "Our GPO sites of care continue to grow, and the team has been busy providing education at conferences across the nation...We've secured more than 15,000 contracted GPO sites, significantly expanding our commercial footprint." William Duke, CFO, stated, "Our PEMGARDA net revenue...
Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Matthew Morris Partridge Chief Financial Officer — Lina Eliwat Need a quote from a Motley Fool analyst? Email [email protected] RISKS Hospitality revenue declined 16% year over year on a pro forma basis, driven by Tin Building underperformance and legacy restaurant softness, only part...
Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Matthew Morris Partridge Chief Financial Officer — Lina Eliwat Need a quote from a Motley Fool analyst? Email [email protected] RISKS Hospitality revenue declined 16% year over year on a pro forma basis, driven by Tin Building underperformance and legacy restaurant softness, only partially offset by event contributions. Landlord segment adjusted EBITDA declined 55% year over year on a pro forma basis, primarily due to $13.4 million of one-time nonrecurring charges from asset write-downs and write-offs. Consolidated segment adjusted EBITDA improvements were achieved with total revenue essentially flat, CFO Eliwat said, "driven by reduced costs as our operating stabilizes." Tin Building closure required a fundamental repositioning due to CEO Partridge citing "historical challenges." TAKEAWAYS Net Loss Improvement -- Full-year net loss attributable to common stockholders was $116.7 million, a 24% improvement; Q4 net loss was $36.9 million, up 11%, both on a year-over-year basis. -- Full-year net loss attributable to common stockholders was $116.7 million, a 24% improvement; Q4 net loss was $36.9 million, up 11%, both on a year-over-year basis. Non-GAAP Adjusted Net Loss -- Non-GAAP adjusted net loss for the year was $54.1 million, a 49% improvement; Q4 non-GAAP adjusted net loss was $17.5 million, up 49%, both year over year. -- Non-GAAP adjusted net loss for the year was $54.1 million, a 49% improvement; Q4 non-GAAP adjusted net loss was $17.5 million, up 49%, both year over year. Revenue -- Total consolidated revenues reached $130.4 million for the full year and $29.5 million in Q4, with Q4 rising 7% year over year and the full year flat versus 2024 on a pro forma basis. -- Total consolidated revenues reached $130.4 million for the full year and $29.5 million in Q4, with Q4 rising 7% year over year and the full year flat versus 2024 on a pro forma basis....
Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Thomas Stepien Chief Financial Officer — Ricardo Rodriguez Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Quarterly Revenue -- $25.2 million, an 18% quarter-over-quarter increase and 137% year-over-year growth. -- $25.2 million, an 18% quarter-over-quarter ...
Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Thomas Stepien Chief Financial Officer — Ricardo Rodriguez Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Quarterly Revenue -- $25.2 million, an 18% quarter-over-quarter increase and 137% year-over-year growth. -- $25.2 million, an 18% quarter-over-quarter increase and 137% year-over-year growth. Full-Year Revenue -- $73 million, tripling the prior year’s total. -- $73 million, tripling the prior year’s total. Quarterly Gross Margin -- 24%, up nine percentage points sequentially and 45 percentage points year over year. -- 24%, up nine percentage points sequentially and 45 percentage points year over year. Full-Year Gross Margin -- 11%, reversing from negative 76% the previous year. -- 11%, reversing from negative 76% the previous year. Operating Loss (Q4) -- $25.4 million, which would have been $2.9 million excluding a $22.5 million one-time charge related to the Colorado facility exit. -- $25.4 million, which would have been $2.9 million excluding a $22.5 million one-time charge related to the Colorado facility exit. Net Loss (Q4, GAAP) -- $24.3 million, or negative $0.18 per share (132.1 million weighted average shares); excluding the one-time charge, net loss would have been $1.9 million or $0.01 per share. -- $24.3 million, or negative $0.18 per share (132.1 million weighted average shares); excluding the one-time charge, net loss would have been $1.9 million or $0.01 per share. Adjusted EBITDA (Q4) -- Negative $1.8 million, with management noting a path to positive adjusted EBITDA if Colorado costs are excluded. -- Negative $1.8 million, with management noting a path to positive adjusted EBITDA if Colorado costs are excluded. Shares Outstanding -- 134.5 million at period end, up by 4.1 million from the prior quarter due to share issuance from option exercises, RSU vesting, and sales under the at-the-market program. -- 13...
SweetBunFactory/iStock via Getty Images Texas Instruments ( TXN ) is combining its real-time control, sensing, and power portfolio tools with Nvidia's ( NVDA ) advanced robotics computing, ethernet-based sensing, and simulation technologies to help developers build and deploy humanoid robots. "TI's comprehensive portfolio bridges the gap between NVIDIA's powerful AI compute and real-world applicat...
SweetBunFactory/iStock via Getty Images Texas Instruments ( TXN ) is combining its real-time control, sensing, and power portfolio tools with Nvidia's ( NVDA ) advanced robotics computing, ethernet-based sensing, and simulation technologies to help developers build and deploy humanoid robots. "TI's comprehensive portfolio bridges the gap between NVIDIA's powerful AI compute and real-world applications, enabling developers to validate complete humanoid systems earlier in development," said Giovanni Campanella, general manager of industrial automation and robotics at Texas Instruments. "This integrated approach will help accelerate the evolution from prototypes to commercially viable humanoid robots operating safely alongside humans." As part of this collaboration, TI designed a sensor fusion solution by integrating its mmWave radar technology with Nvidia Jetson Thor using Nvidia Holoscan Sensor Bridge to enable low-latency, 3D perception and safety awareness for humanoid robots. Texas Instruments plans to showcase the development during the upcoming Nvidia GTC event, which runs from March 16 through 19 in San Jose, Calif. "The safe operation of humanoid robots in unpredictable environments requires a massive leap in processing power to synchronize complex AI models with real-time sensor data and motor controls," said Deepu Talla, vice president of robotics and edge AI at Nvidia. By fusing camera and radar data, the solution improves object detection, localization, and tracking while reducing false positives for confident, real-time decision-making in humanoid robots, the companies said. Several U.S.-based companies are working to develop humanoid robots. Tesla ( TSLA ) is busy developing Optimus, a humanoid bot being built for industrial and consumer uses. Figure AI, which is backed by Microsoft ( MSFT ) and OpenAI ( OPENAI ), is attempting to craft a general-purpose humanoid capable of handling all types of tasks. "These robots can eliminate the need for unsafe and ...
Paavan Kotini's recent #1 Amazon New Release & Best Seller empowers physicians to reclaim millions in lifetime earnings and cut six-figure annual taxes via his revolutionary Doctors & Dentists Family Office model. RICHMOND, Va., March 5, 2026 /PRNewswire/ -- Physicians and dentists can lose millions of dollars in lifetime earnings due to poor tax planning, not because they earn too little, but bec...
Paavan Kotini's recent #1 Amazon New Release & Best Seller empowers physicians to reclaim millions in lifetime earnings and cut six-figure annual taxes via his revolutionary Doctors & Dentists Family Office model. RICHMOND, Va., March 5, 2026 /PRNewswire/ -- Physicians and dentists can lose millions of dollars in lifetime earnings due to poor tax planning, not because they earn too little, but because they were never taught how to plan. In a new book, Tax Efficient White Coat , Richmond-based author and financial strategist Paavan Kotini argues that this widespread gap in financial education is quietly fueling burnout, stress, and long-term wealth loss across the medical profession. Kotini & Kotini Logo Kotini's book, Tax Efficient White Coat , which recently became a #1 Amazon New Release, outlines a coordinated tax and wealth planning framework designed specifically for physicians. The approach created by Kotini & Kotini , called the Doctors & Dentists Family Office (DFO) model, brings CPAs, attorneys, and financial advisors together under a single strategy, replacing the siloed decision-making that often leaves high-earning doctors exposed to unnecessary tax liability. "Doctors are trained to diagnose problems early and treat them comprehensively," Kotini said. "But when it comes to their finances, they're often forced to piece things together on their own. The result is preventable financial bleeding that compounds over decades." In Tax Efficient White Coat , Kotini breaks down complex tax strategies into practical, compliance-driven systems, covering topics such as advanced deductions, depreciation strategies, charitable structures, and long-term insurance planning. The book frames financial literacy as a form of preventative care, emphasizing peace of mind alongside wealth preservation through what Kotini calls the S.W.A.N.™ framework — Sleep Well At Night. Dr. Tracy Gapin, a physician, author, and healthcare performance expert who wrote the book's foreword, n...
South Africa’s president, Cyril Ramaphosa, has called Donald Trump’s policy of allowing white Afrikaners to apply for refugee status in the US “racist”, saying the US president was “truly uninformed” in a rare instance of direct criticism. Ramaphosa told the New York Times that last year’s Oval Office meeting with the US leader, when Trump turned down the lights and played a video that he falsely ...
South Africa’s president, Cyril Ramaphosa, has called Donald Trump’s policy of allowing white Afrikaners to apply for refugee status in the US “racist”, saying the US president was “truly uninformed” in a rare instance of direct criticism. Ramaphosa told the New York Times that last year’s Oval Office meeting with the US leader, when Trump turned down the lights and played a video that he falsely claimed showed there was a “white genocide” in South Africa, was a “spectacle” and an “ambush”. “I just thought that he is so uninformed, truly uninformed,” Ramaphosa said. “I realised that he is looking at South Africa through a completely, sort of, foggy lens, without realising the real, real harm that apartheid did. In my view, he was just dismissive.” Trump has targeted South Africa since starting his second term in office in January 2025. He has spread false allegations that the country’s white minority are undergoing a “genocide” and that their land is being seized by the government. In May, the US extended refugee status to Afrikaners – who once led the repressive minority apartheid government and who remain on average many times wealthier than Black South Africans – while slashing its refugee programme for people fleeing war and persecution. Trump refused to attend the G20 leaders meetings in Johannesburg in November and has banned South Africa from attending the US-hosted gathering in Miami later this year. “I do think the Afrikaner policy is racist,” Ramaphosa said. “It is that racist sort of demeanour that we want to be able to whittle down so that he can see the truth of the situation.” In a statement to the New York Times, the White House said that Trump was calling attention to “the harrowing stories of Afrikaners”. It said: “The South African government, at minimum, does not respond, but President Trump has a humanitarian heart. He will continue to speak the truth about these injustices.” Ramaphosa said: “There’s no white genocide and there is no grabbing of ...
Investors in Archer Aviation Inc (Symbol: ACHR) saw new options begin trading today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACHR options chain for the new April 24th contracts and identified the following put contract of particular interest. The put contract at the $6.50 strike price has a current bid of 2 cents. If an investor w...
Investors in Archer Aviation Inc (Symbol: ACHR) saw new options begin trading today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACHR options chain for the new April 24th contracts and identified the following put contract of particular interest. The put contract at the $6.50 strike price has a current bid of 2 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $6.50, but will also collect the premium, putting the cost basis of the shares at $6.48 (before broker commissions). To an investor already interested in purchasing shares of ACHR, that could represent an attractive alternative to paying $6.58/share today. Because the $6.50 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.31% return on the cash commitment, or 2.25% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Archer Aviation Inc, and highlighting in green where the $6.50 strike is located relative to that history: The implied volatility in the put contract example above is 142%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $6.58) to be 81%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Puts of the S&P 500 »...
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the CRSP options chain for the new April 24th contracts and identified one put and one call contract of particular interest. The put contract at the $57.00 strike price has a current bid of $2.50. If an inves...
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the CRSP options chain for the new April 24th contracts and identified one put and one call contract of particular interest. The put contract at the $57.00 strike price has a current bid of $2.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $57.00, but will also collect the premium, putting the cost basis of the shares at $54.50 (before broker commissions). To an investor already interested in purchasing shares of CRSP, that could represent an attractive alternative to paying $57.96/share today. Because the $57.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 60%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.39% return on the cash commitment, or 32.04% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for CRISPR Therapeutics AG, and highlighting in green where the $57.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $61.00 strike price has a current bid of $2.70. If an investor was to purchase shares of CRSP stock at the current price level of $57.96/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $61.00. Considering the call s...
Investors in Autodesk Inc (Symbol: ADSK) saw new options become available today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ADSK options chain for the new April 24th contracts and identified one put and one call contract of particular interest. The put contract at the $260.00 strike price has a current bid of $8.80. If an investor wa...
Investors in Autodesk Inc (Symbol: ADSK) saw new options become available today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ADSK options chain for the new April 24th contracts and identified one put and one call contract of particular interest. The put contract at the $260.00 strike price has a current bid of $8.80. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $260.00, but will also collect the premium, putting the cost basis of the shares at $251.20 (before broker commissions). To an investor already interested in purchasing shares of ADSK, that could represent an attractive alternative to paying $261.96/share today. Because the $260.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 58%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.38% return on the cash commitment, or 24.73% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Autodesk Inc, and highlighting in green where the $260.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $300.00 strike price has a current bid of $2.70. If an investor was to purchase shares of ADSK stock at the current price level of $261.96/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $300.00. Considering the call seller wi...
In trading on Thursday, shares of PT Telekomunikasi Indonesia TBK (Symbol: TLK) crossed below their 200 day moving average of $19.45, changing hands as low as $19.34 per share. PT Telekomunikasi Indonesia TBK shares are currently trading off about 4% on the day. The chart below shows the one year performance of TLK shares, versus its 200 day moving average: Looking at the chart above, TLK's low po...
In trading on Thursday, shares of PT Telekomunikasi Indonesia TBK (Symbol: TLK) crossed below their 200 day moving average of $19.45, changing hands as low as $19.34 per share. PT Telekomunikasi Indonesia TBK shares are currently trading off about 4% on the day. The chart below shows the one year performance of TLK shares, versus its 200 day moving average: Looking at the chart above, TLK's low point in its 52 week range is $13.15 per share, with $23.515 as the 52 week high point — that compares with a last trade of $19.37. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jerry Durso Chief Medical Officer — Christophe Arbet-Engels Chief Commercial Officer — Linda Richardson Chief Financial Officer — Greg Weaver [Unspecified Manufacturing Executive] — M. Roberts Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS R&D Expense -- $1...
Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jerry Durso Chief Medical Officer — Christophe Arbet-Engels Chief Commercial Officer — Linda Richardson Chief Financial Officer — Greg Weaver [Unspecified Manufacturing Executive] — M. Roberts Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS R&D Expense -- $18.4 million for the quarter, down from $19.8 million in 2024, reflecting the end of the Phase IIb trial. -- $18.4 million for the quarter, down from $19.8 million in 2024, reflecting the end of the Phase IIb trial. G&A Expense -- $10.5 million, compared to $5.1 million in the same quarter of 2024, with a $2.6 million executive transition charge and increased professional fees and compensation costs. -- $10.5 million, compared to $5.1 million in the same quarter of 2024, with a $2.6 million executive transition charge and increased professional fees and compensation costs. Full-Year Net Loss -- $27.4 million, or $0.27 per share, compared to $23.2 million, or $0.33 per share, in 2024. -- $27.4 million, or $0.27 per share, compared to $23.2 million, or $0.33 per share, in 2024. Total Cash at Year-End -- $274 million following $208 million in net proceeds ($174 million equity capital, $35 million Hercules loan facility), with a further $75 million raised in January and $8 million from the ATM facility, leading to a pro forma cash position of approximately $340 million. -- $274 million following $208 million in net proceeds ($174 million equity capital, $35 million Hercules loan facility), with a further $75 million raised in January and $8 million from the ATM facility, leading to a pro forma cash position of approximately $340 million. Planned Cash Runway -- Management forecasts current cash will fund operations through 2028, covering the NASH Phase III trial and ongoing AUD and ALD Phase II studies. -- Management forecasts current cash will fund operations through 2028, cover...